Tau PET is central to Alzheimer's diagnosis and trial selection. But does tracer choice matter? The HEAD study set out to answer that. 682 participants, both Flortaucipir and MK6240, across the Alzheimer's spectrum. Out today in @thelancet.com. Article link: t.co/56RqoX9Uaq